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doi:10.1016/j.ejvs.2008.04.015Abstract Objectives: Continued haemorrhage remains a significant contributor to mortality
in massively transfused patients. We found that early administration of platelets and plasma
reduced mortality from 54% to 36% in rAAA patients. The aim of the present evaluation was
to evaluate whether reduced mortality in rAAA patients related to a pro-active transfusion
therapy is maintained.
Design: Single-centre observational study.
Methods: Mortality of patients operated for rAAA 2006e07 was compared to that of patients
operated 2004e05 (intervention group; nZ 50) and 2002e04 (control group, nZ 82).
Results: 64 consecutive patients with rAAA received, similar to the intervention group, more
platelets (5 and 4 vs. 0 units, P< 0.05) and plasma (12 and 11 vs. 7 units, P< 0.05) intraopera-
tively and had a higher platelet count (158 and 155 vs. 69 109/L, P< 0.0001) upon arrival at
the intensive care unit and the 30-day mortality remained reduced (24% and 36% vs. 56%,
P< 0.01 and PZ 0.02, respectively) as compared to the control patients.
Conclusions: Early administration of platelets and plasma, together with red blood cells main-
tained reduced mortality in patients operated for rAAAin a 18 month period.
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Continued haemorrhage remains a significant contributor to
mortality in massively transfused patients and many
patients develop coagulopathy.1 Patients surviving massive
transfusion have a higher platelet count2 and a shorter pro-
thrombin (PT) and activated partial thrombin time (APTT)3d by Elsevier Ltd. All rights reserved.
398 P.I. Johansson et al.than non-survivors and maintained coagulation competence
appears to be of importance for haemostasis and, thereby,
survival.4,5
Current transfusion recommendations appear to be
extrapolated from elective surgery and may not be appli-
cable to patients with massive bleeding who are likely to be
hypocoagulable because of hypothermia, acidosis, and
haemorrhagic shock.6 The recommended resuscitation
regimen advocates early administration of crystalloids and
colloids supplemented by administration of fresh frozen
plasma (FFP) and platelets only when one whole blood vol-
ume is replaced and this may further impair haemostatic
competence.7 Thus, administration of FFP and platelet con-
centrates (PC), in addition to red blood cells (RBC), as
a part of a transfusion package, immediately when the
patient with a ruptured abdominal aortic aneurysm (rAAA)
arrives at the hospital and throughout surgery, appears to
reduce mortality in these patients.8 Survival was related
to maintenance of haemostatic competence, resulting in
reduction in postoperative transfusion requirements. How-
ever, survivals in these rAAA patients vary from year to year
and it may be that the reduced mortality following intro-
duction of a balanced blood transfusion strategy resulted
from such random variation in mortality following rAAA
surgery.9
We hypothetizised that administration of transfusion
packages would maintain a reduced mortality in rAAA
patients and, hence, the aim of this observational follow-
up study was to evaluate whether the reduced mortality in
rAAA patients was maintained in patients undergoing rAAA
surgery in the 18-months following the end of the first
evaluation of the change in transfusion strategy.
Material and Methods
The background of the study was an observational study of
all patients operated for a rAAA from January 1st 2006 to
June 30th 2007. Data were collected and entered into
a study database according to a unique personal identity
number after approval from the Danish Data Protection
Agency. Consent was not obtained as Danish legislation
allows database studies without approval from the ethics
committee system and the local ethics committee did not
endorse a randomized trial. In Denmark, treatment of
acute AAA takes place in six centers and this hospital cover
70% of the Eastern part of the country. Throughout the
period of the study (2002e2007) there were no deliberate
changes in referral practice or surgical procedures and
specifically there were no identified change from the period
before implementation of the revised transfusion strategy
to the present follow-up study. The diagnosis of rAAA was
established by an ultrasound image at the local hospital and
that was confirmed at the hospital the patient was referred
to for surgery. The surgical procedure employed laparot-
omy and no endovascular repair was performed. The
transfusion strategy included administration of platelets
and FFP together with RBC as a part of a transfusion
package immediately the patient arrived at the hospital
and continued throughout surgery. In addition, two PC were
administered before reperfusion of the aorta and for the
patients included in this follow-up study also tranexamic
acid 2 g i.v., considering that this may further improvehaemostatic competence, was administered at induction
of anaesthesia and further 1 g was administered at reperfu-
sion of the aorta.
Transfusion requirements and mortality of these
patients were compared to those of patients operated for
a rAAA from 2002e2005. Patients operated for a rAAA
between January 1st 2002 and April 30th 2004 constituted
a control group that had been transfused according to
existing guidelines as outlined above. Patients operated for
an acute AAA was identified from the national vascular
database and those presenting with intra eor retroperito-
neal haematoma during dissection of the aorta as stated in
the surgical record were included. The national vascular
database also identified those patients transferred directly
to the referral hospital and those who were transferred
through another hospital. The intervention group, identi-
fied as described above was treated with transfusion
packages, from May 1st 2004 until 2006.
For the follow-up group, data were collected on patients
undergoing rAAA surgery during the study period and
a review of their records was conducted with respect to
presence of intra eor retroperitoneal haematoma during
dissection of the aorta, gender, age, weight, co-morbidities
defined as diabetes type I, cerebrovascular disease
including stroke, TCI, intracranial bleeding, hypertension,
cardiovascular disease including myocardial infarction,
angina pectoris, and pulmonary disease including chronic
obstructive pulmonary disease and asthma. Furthermore,
the peri operative blood loss, supra/infra renal aortic
clamping position and clamping time, duration of surgery,
re-do surgery, length of stay (LOS) in the intensive care unit
(ICU), LOS in hospital, and 30-day mortality were noted.
Time and amount of transfused RBC, FFP, and PC were
obtained from the database in the blood bank. Haemoglo-
bin, platelet count, activate partial thromboplastin time
(APTT), international normal ratio (INR), and serum creat-
inine at admission to the ICU following the operation were
obtained from the laboratory database.
All patients received the same anaesthetic regimen
including preoxygenation followed by rapid sequence
induction and relaxation with suxamethonium follwed by
endo tracheal intubation and mechanical ventilation.
Anaestheisa was maintained by inhalation of sevoflurane.
Volume replacement was individually goal- directed to
maintain maximal venous oxygen saturation.10 Lactated
Ringers solution and RBC were administered to maintain
a haematocrit of 30%. No cell saver was used to maintain
coagulation competence and all blood products and fluids
administered were pre-warmed to maintain patients´ tem-
perature atw37 C with use of external heating. Data anal-
ysis was performed using SAS 9.1 (Cary, NC, USA) and are
presented as median and range. Results were compared
using the two-sample Wilcoxon rank sum test or Fisher’s
exact test as appropriate with a p-value< 0.05 considered
as statistically significant.Results
Records of 64 consecutive patients operated for rAAA were
identified from 2006 to 2007 (18 months) and there were no
significant differences between the follow-up and the
Table 1 Descriptive data for patients operated for a rup-
tured abdominal aortic aneurysm
Follow-up
group
Intervention
group
Control
group
Year 2006e2007 2004e2005 2002e2004
Number 64 50 82
Patient
Characteristics
Male/Female 55/9 43/7 72/10
Age, Median
(range) years.
77
(62e90)
71
(48e89)
73
(51e84)
Weight (kg) 83
(53e124)
77
(55e100)
80
(35e115)
Medical history
No. (%)
Co-morbidity 75% 73% 74%
Diabetes 12% 11% 10%
Cerebrovascular 12% 11% 9%
Hypertension 45% 41% 37%
Mortality Following rAAA Surgery 399control or intervention groups of patients in regard to
baseline characteristics (Table 1).
The 30-day mortality in the follow-up group was 25%, not
being significantly different from the intervention group
(34%, PZ 0.29), whereas both of these groups presented
with a lower mortality when compared to that of the
control group (56%; P< 0.01 and PZ 0.02, respectively).
No significant differences in RBC requirements were found
between groups, whereas both the follow-up and interven-
tion group received more FFP (12 and 11 vs. 7 units,
P< 0.05), and platelets (5 and 4 vs. 0 units, P< 0.05) as
compared to the control group (Table 2). In the ICU, how-
ever, the control group received more RBC (6 vs. 3 and 2
units respectively, P< 0.05), FFP (4 vs. 2 and 2 units,
P< 0.05), and PC (1 vs. 0 and 0 units, P< 0.05) as compared
to patients receiving transfusion packages intraoperatively.
The follow-up as well as the intervention groups had
a higher platelet count (158 and 155 vs. 69 109/L.,
P< 0.0001) and shorter APTT upon arrival at the ICU
(38 and 39 vs. 44 s, P< 0.05).Cardiac disease 24% 25% 27%
Pulmonary
disease
22% 20% 18%
Surgery
Tube graft 40 35 60
Bifurcated graft 24 15 22
Clamping position
(S/I)
3/61 4/46 4/78
Clamping time
(min) Median
(range)
94
(35e224)
96
(50e140)
97
(40e205)
Surgery (min) 191
(105e320)
183
(120e300)
194
(120e400)
Bleeding (L) 5,8
(1,5e15)
6.1
(0.6e20.0)
6.3
(1.0e27.0)
Re-do surgery (No). 4 5 11
Re-do survival (No). 2 2 3
Suprarenal/Infrarenal clamping position (S/I).Discussion
The principal finding of this 18 month follow-up study is
that administration of a balanced transfusion strategy
through provisions of ‘‘transfusion packages’’, encompass-
ing PC and FFP together with RBC, provided from the start
of surgery and repeated during surgery as needed, main-
tained a reduced mortality rate in patients operated for
a rAAA, as compared to a historical control group of
patients treated in accordance to recommendations from
existing transfusion guidelines.7 Following the local change
in transfusion practice,patients received more PC and FFP
intraoperatively and they had a higher platelet count and
a shorter APTT when entering the ICU than was the case
for the historic control group of patients. Administration
of tranexamic acid to the rAAA patients may have contrib-
uted to enhance the survival of the patients although this
finding was not statistically significant when compared to
when the change in blood component usage was
introduced.
Implementation of a transfusion protocol for massively
bleeding patients to provide timely and balanced delivery
of blood components aimed at preventing, rather than to
‘‘catch up’’ with coagulopathy as it develops, and that
appeared to maintain a low mortality rate for patients
operated for a rAAA.11 Both the follow-up and the interven-
tion groups of patients operated for rAAA presented with
a platelet count well above 100 109/L upon arrival at
the ICU, while the control group was thrombocytopenic,
although the value was above the presently recommended
level of 50 109/L. The control group received more trans-
fusions in the ICU, suggesting improved haemostatic ability
in the groups of patients receiving transfusion packages.
This apparent increased coagulation competence con-
curred with findings in patients presenting with uncon-
trolled haemorrhage receiving transfusion packages and
monitored by thrombelastography (TEG) before and after
each package, who demonstrate normal haemostatic com-
petence even when up to 7 packages are administered.12
Accordingly, experience from the Iraqi war supports thatpatients having a high FFP to RBC ratio and receiving
more platelets demonstrate a lower mortality rate than
those receiving less plasma and platelets following
trauma.13
Mortality of patients operated for a rAAA ranged from
40% to 70% with a mean of w50% in the years before the
introduction of a balanced blood component therapy by
predefined packages of blood products. Thus, with
introduction of the transfusion packages mortality
decreased to 36% and, as demonstrated in this follow-up
study, stabilized below 30%.
Transfusion medicine is a young speciality and its
members are largely drawn from among clinical patholo-
gists or haematologists and its concerns are focused on how
to keep blood banks and transfusion services staffed,
licensed, accredited and supplied.6 Those in charge of
organising and maintaining a transfusion service have, in
general, little clinical experience and focus is on standard
operating procedures and evidence based guidelines. The
majority of the evidence and, accordingly, the guidelines
released during the past two decades suggest that
Table 2 Outcome data for patients operated for a ruptured abdominal aortic aneurysm
Follow-up group Intervention group Control group
Year 2006e2007 2004e2005 2002e2004
Transfusions intraoperatively (No)
RBC 10 (3e24) 12 (2e40) 10 (4e65)
FFP 12 (4e24) 11 (2e42) *7 (0e46)
PC 5 (3e11) 4 (2e16) *0 (0e3)
Transfusions postoperatively (No.)
RBC 2 (0e20) 3 (0e31) *6 (0e54)
FFP 2 (0e10) 2 (0e12) *4 (0e32)
PC 0 (0e5) 0 (0e4) *1 (0e6)
Laboratory values
at admission to ICU
Haemoglobin (g/L) Median (range) 122 (78e150) 123 (72e171) 121 (105e134)
Platelet count (109/L) 158 (77e286) 155 (31e557) *69 (29e236)
APTT (s) 36 (20e124) 39 (22e130) *44 (28e145)
INR (arbitrary units) 1.2 (0.8e3.9) 1.3 (0.9e4.2) 1.3 (1.0e2.1)
S-Creatinine (mg/dL) 1.3 (0.65e7.3) 1.3 (0.52e9.2) *1.7 (0.91e5.2)
Length of stay (LOS)
ICU (d) 5.5 (0e22) 6.3 (0e26) 4.2 (0e33)
Hospital (d) 11.1 (1e47) 12.0 (1e42) 10.0 (1e86)
Activated partial thromboplastintime (APTT); prothrombintime (PT); all values for arrival at the intensive care unit (ICU) after surgery.
Data are median and range. *difference between the follow-up and intervention vs. control group (p< 0.05).
400 P.I. Johansson et al.administration of less blood is better, but the caveat is that
these guidelines apply to haemodynamically stable
patients.6 The data presented here adds to the body of
reports14e17 corroborating that early administration of
platelets and FFP, together with RBC appear to be associ-
ated with improved survival in massively bleeding patients
and suggest that maintained coagulation competence is
important for patients operated for a rAAAAcknowledgements
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